upcoming glp 1 drugs Dozens of new obesity are coming: these are the ones to watch GLP-1 Market Trends and Global

Description

It is found that in the clinical follow-up studies of NAFLD patients, compared with the control group, hepatic fat content and ALT levels were not significantly reduced in Lira group and were associated with an increased incidence of gastrointestinal adverse events [118]

This is an important and evolving topic

Before joining The Post, Miska covered lifestyle and consumer topics for the U.S

[DOI] [PMC free article] [PubMed] [Google Scholar] 119.Ratner RE, Rosenstock J, Boka G

[33] [34] In 2026, the UK Medicines and Healthcare products Regulatory Agency (MHRA) updated its guidance on GLP-1 medication after an increase in reports to the agency's Yellow Card Scheme of acute pancreatitis, with fatalities, in patients taking semaglutide or tirzepatide, to warn of a small risk of developing severe acute pancreatitis